MCRS1 and neoplasm: Fudan University’s team led by Xiao Fei has revealed that MCRS1 can enhance the sensitivity of tumor cells to T-cell killing by upregulating MHC-I molecule expression in solid tumors, while improving the therapeutic effect of PD-1 blockade therapy (18).